Quantum Leap for Medicine: CQT and Qubit Pharmaceuticals Forge Strategic Alliance to Redefine Drug Discovery
The Center for Quantum Technologies (CQT) and Qubit Pharmaceuticals formally joined forces in a historic partnership that heralds a new era for the pharmaceutical sector. The goal of this two-year strategic research collaboration is to bring quantum computing into the domain of practical drug development rather than just theoretical study. By employing cutting-edge quantum technology and algorithmic design, the researchers seek to solve some of medicine’s biggest computational bottlenecks.
You can also read An Open Quantum systems approach to Proton tunneling in DNA
Bridging the Gap: Physics Meets Pharma
This collaboration’s main goal is to overcome a basic obstacle in the medical sciences: quantum drug discovery is fundamentally a huge molecular simulation problem. Scientists must comprehend how millions of possible chemicals interact with biological targets like proteins or RNA to find a single promising therapeutic candidate. However, when trying to represent these intricate interactions at a high-fidelity quantum level, conventional computational approaches frequently encounter a “curse of dimensionality” problem.
Drug property forecasts may be inaccurate due to approximations used by even the most potent high-performance computing (HPC) systems available today. The goal of the CQT-Qubit partnership is to replace these approximations with high-fidelity modeling that is theoretically only possible with quantum computers. Although quantum algorithms for chemistry have been researched for decades, real-world applications have remained incredibly rare, as Robert Marino, CEO of Qubit Pharmaceuticals, pointed out during the Quantum Industry Day in Singapore. This cooperation aims to change that by translating theoretical principles into computational tools.
You can also read XeedQ XQ1 Gets Automated Quantum Bring-Up With Qruise
A Synergy of Expertise and Innovation
Complementary strengths underpin the collaboration. As demonstrated by its Atlas platform, Qubit Pharmaceuticals offers a wealth of knowledge in quantum chemistry and sophisticated sampling methods. Since its establishment in 2020, the company has used quantum-inspired AI and hybrid HPC to speed up drug development.
Conversely, a wealth of skill in quantum circuit design, algorithm development, and experimental implementation is available at the Centre for Quantum Technologies. CQT is at the vanguard of national quantum activities and is based across three major universities in Singapore: the National University of Singapore, Nanyang Technological University, and Singapore University of Technology and Design, in addition to A STAR. Because of their collaboration, the teams are able to create and evaluate algorithms like quantum phase estimation (QPE), variational quantum eigensolvers (VQE), and quantum Markov Chain Monte Carlo (qMCMC) sampling that are especially suited to the high-stakes demands of the pharmaceutical industry.
You can also read Paragraf Company with Archer Materials Quantum Computing
Breaking New Ground: The qMCMC Implementation
The collaboration has already produced notable outcomes. On April 23, 2026, researchers from both institutions presented their initial experimental results during a Quantum Industry Day that was attended by about 250 people. The effective implementation of the qMCMC algorithm on actual quantum hardware was one of the main highlights. The team has published its results on the physics preprint server arXiv, and this is the first time such an algorithm has been implemented on actual hardware.
Because classical drug discovery mostly uses Markov chains to sample probability distributions for molecular simulations, the qMCMC approach is especially important. Researchers can sample molecular conformations far more efficiently with the quantum version’s potential for quadratic speedups. The team is going beyond abstract demonstrations to address practical computational bottlenecks in chemistry by evaluating different encodings on actual hardware.
You can also read Lip Bu Tan Intel News Joins PsiQuantum for Quantum Computing
The Power of the Hardware Ecosystem
Having access to cutting-edge hardware is essential to these experiments’ success. CQT researchers have access to some of the greatest gate-based quantum computers in the world, including Quantinuum‘s H2 and Helios trapped-ion systems, through Singapore’s National Quantum Computing Hub.
Lead researcher at CQT Sergi Ramos-Calderer stressed that advances in algorithm design must coincide with advancements in hardware. The team is able to assess precisely what is needed to make quantum algorithms effective for real chemical discovery by testing these techniques under realistic conditions on devices such as the H2.
Determining which techniques can offer a clear “quantum advantage” the point at which quantum systems surpass the most potent classical supercomputers on particular chemical tasks requires an iterative process of validating algorithms on simulators before implementing them on actual quantum hardware.
You can also read India and Japan Quantum Alliance 2026: A Era of Tech Power
The Path to High-Fidelity Simulations
The research team is improving other important algorithms in addition to qMCMC. The ground-state energies of molecules, which are crucial for figuring out molecular stability and binding affinity, are being calculated using Variational Quantum Eigensolvers (VQE). Concurrently, the group is investigating Quantum Phase Estimation (QPE) to attain the maximum levels of simulation accuracy. This accuracy may make it possible to anticipate pharmacological characteristics that were previously thought to be “unmodelable” using traditional methods.
The team’s goal as the partnership grows is to produce molecular simulation data straight from quantum algorithms and incorporate these capabilities into upcoming drug discovery processes. Pharmaceutical businesses can make better decisions far earlier in the development pipeline if chemistry can be modeled with higher realism and efficiency, according to Jean-Philip Piquemal, Chief Scientific Officer and co-founder of Qubit Pharmaceuticals.
You can also read MOPA Enables Multimode Squeezed Light Real-Time Monitoring
Future Outlook: A Bridge to the 2030s
The collaboration between CQT and Qubit Pharmaceuticals is considered a crucial “bridge” project for the sector. Although it is anticipated that large-scale, fault-tolerant quantum computing won’t be fully developed until the early 2030s, current efforts mark the shift from scientific promise to usefulness.
Through the direct integration of “native” quantum algorithms into discovery pipelines, the collaborators expect to eventually lower the enormous expenses and delays involved in providing patients with safer, more effective medications. The objective, according to José Ignacio Latorre, Director of CQT, is to create algorithms that address the issues that people are most concerned about to keep up with the quick speed of hardware advancement. In addition to establishing Singapore as a preeminent worldwide center for quantum computing, the partnership offers a roadmap for how quantum technology will address the most difficult medical problems in the years to come.
You can also read Integrated Photonics for Continuous-Variable Quantum Optics
